Drugs / ADX-850
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06205628 | Mar 2024 → Jul 2026 overdue | essential hypertension | ADARx Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-01 | ADARx Pharmaceuticals, Inc. | Safety, Tolerability, PK and PD of ADX-850 in Participants with Hypertension adarx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADX-850 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205628 ↗ |